Innate Pharma FY2029 EPS Forecast Lifted by HC Wainwright

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Investment analysts at HC Wainwright increased their FY2029 earnings per share (EPS) estimates for shares of Innate Pharma in a report issued on Monday, September 21st. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.30 for the year, up from their previous forecast of $0.23. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Innate Pharma’s FY2030 earnings at $0.61 EPS.

IPHA has been the topic of a number of other reports. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a research report on Tuesday, August 11th. Leerink Partners raised Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 26th. BTIG Research restated a “buy” rating and set a $9.00 price target on shares of Innate Pharma in a report on Thursday, September 17th. Finally, Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research note on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Innate Pharma Price Performance

IPHA opened at $1.86 on Tuesday. The stock has a fifty day moving average of $1.98 and a 200-day moving average of $1.75. Innate Pharma has a fifty-two week low of $1.17 and a fifty-two week high of $2.71.

About Innate Pharma

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma’s pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.